Los Angeles Capital Management LLC Has $3.82 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Los Angeles Capital Management LLC lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 103,284 shares of the biopharmaceutical company’s stock after purchasing an additional 1,987 shares during the period. Los Angeles Capital Management LLC owned 0.08% of Halozyme Therapeutics worth $3,817,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of HALO. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $1,030,000. Harvey Capital Management Inc. acquired a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $5,918,000. Hsbc Holdings PLC increased its stake in Halozyme Therapeutics by 35.0% in the third quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company’s stock valued at $3,006,000 after purchasing an additional 20,346 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Halozyme Therapeutics by 174.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after purchasing an additional 563,989 shares during the period. Finally, Aurora Investment Counsel acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $1,347,000. Institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on HALO. JMP Securities reissued a “market outperform” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. The Goldman Sachs Group cut their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 30th. Finally, StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Stock Performance

HALO opened at $39.91 on Monday. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics, Inc. has a 12-month low of $29.85 and a 12-month high of $45.00. The business has a 50 day moving average of $39.99 and a 200-day moving average of $37.91. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 18.91, a PEG ratio of 0.47 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $39.55, for a total transaction of $395,500.00. Following the completion of the sale, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,191,868.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 30,000 shares of company stock worth $1,196,800. Insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.